Should I buy or sell Neumora Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neumora Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NMRA shares. View NMRA analyst ratings or view top-rated stocks .

What is Neumora Therapeutics' stock price target for 2024?

7 analysts have issued 12 month target prices for Neumora Therapeutics' shares. Their NMRA share price targets range from $13.00 to $26.00. On average, they anticipate the company's share price to reach $21.29 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View analysts price targets for NMRA or view top-rated stocks among Wall Street analysts .

How have NMRA shares performed in 2024?

Neumora Therapeutics' stock was trading at $17.05 at the start of the year. Since then, NMRA stock has increased by 8.0% and is now trading at $18.42. View the best growth stocks for 2024 here .

When is Neumora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024. View our NMRA earnings forecast .

How were Neumora Therapeutics' earnings last quarter?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.79.

When did Neumora Therapeutics IPO?

(NMRA) raised $250 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

When does Neumora Therapeutics' lock-up period expire?

Neumora Therapeutics' lock-up period expires on Wednesday, March 13th. Neumora Therapeutics had issued 14,710,000 shares in its IPO on September 15th. The total size of the offering was $250,070,000 based on an initial share price of $17.00. After the end of Neumora Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Neumora Therapeutics' major shareholders?

Neumora Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (0.09%), Norges Bank (0.03%), New York State Common Retirement Fund (0.00%), SG Americas Securities LLC (0.00%), Strs Ohio (0.00%) and Amalgamated Bank (0.00%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Henry O Gosebruch and Kristina Burow. View institutional ownership trends .

How do I buy shares of Neumora Therapeutics?

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NMRA

Neumora Therapeutics (NMRA) Stock Price, News & Analysis

$18.42

+0.97 (+5.56%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $17.27
▼
$18.49
50-Day Range: $11.78
▼
$18.42
52-Week Range: $9.35
▼
$19.30

Volume: 208,600 shs
Average Volume: 196,921 shs
Market Capitalization: $2.81 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.29

Get Neumora Therapeutics alerts:

Neumora Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 15.6% Upside
$21.29 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$412,140 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.91) to ($2.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars

Medical Sector

858th out of 922 stocks

Biological Products, Except Diagnostic Industry

144th out of 154 stocks

2.4

Analyst's Opinion

Consensus Rating
Neumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.29, Neumora Therapeutics has a forecasted upside of 15.6% from its current price of $18.42.
Amount of Analyst Coverage
Neumora Therapeutics has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for NMRA.

0.0

Dividend Strength

Dividend Yield
Neumora Therapeutics does not currently pay a dividend.
Dividend Growth
Neumora Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NMRA.

2.2

News and Social Media Coverage

News Sentiment
Neumora Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Neumora Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neumora Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $412,140.00 in company stock and sold $0.00 in company stock.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Neumora Therapeutics are expected to decrease in the coming year, from ($1.91) to ($2.29) per share.

See Top Rated MarketRank™ Stocks Here

About Neumora Therapeutics Stock (NASDAQ:NMRA)

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

NMRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NMRA Stock News Headlines

February 8, 2024 | seekingalpha.com

Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling

January 22, 2024 | finance.yahoo.com

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

January 10, 2024 | finance.yahoo.com

Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick

January 5, 2024 | seekingalpha.com

NMRA Neumora Therapeutics, Inc.

January 2, 2024 | finance.yahoo.com

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024 | seekingalpha.com

Neumora: Novel Neuroscience Player, But Valuation Is Too High

December 22, 2023 | morningstar.com

Neumora Therapeutics Inc NMRA

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

December 22, 2023 | msn.com

Bristol-Karuna deal: What other biotechs might be in M&A crosshairs?

December 22, 2023 | benzinga.com

Neumora Therapeutics Stock (NASDAQ:NMRA) Dividends: History, Yield and Dates

December 12, 2023 | finanznachrichten.de

Neumora Therapeutics, Inc.: Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

December 12, 2023 | finance.yahoo.com

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

November 27, 2023 | markets.businessinsider.com

Neumora Therapeutics Begins Phase 1 Study With NMRA-266 - Quick Facts

November 27, 2023 | finance.yahoo.com

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

November 9, 2023 | benzinga.com

Neumora Therapeutics Stock (NASDAQ:NMRA), Analyst Ratings, Price Targets, Predictions

November 1, 2023 | finanznachrichten.de

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023 | finanznachrichten.de

Neumora Therapeutics Announces IPO Of 14.71 Mln Shares To Be Priced Between $16.00 And $18.00/Share

November 1, 2023 | finance.yahoo.com

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

October 30, 2023 | finance.yahoo.com

Neumora Therapeutics to Participate in Upcoming Conferences in November

October 18, 2023 | seekingalpha.com

Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades

October 10, 2023 | in.investing.com

Neumora Therapeutics started with Buy ratings at several Wall Street firms

October 10, 2023 | cnbc.com

Buy this 'game-changer' biotech stock with more than 50% upside, BofA says

October 10, 2023 | markets.businessinsider.com

Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug

October 10, 2023 | markets.businessinsider.com

Neumora Therapeutics: A Promising Buy with Diversified Pipeline and High Upside Potential

October 10, 2023 | finance.yahoo.com

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

September 21, 2023 | fool.com

Neumora Therapeutics (NASDAQ: NMRA)

See More Headlines

Receive NMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 2/12/2024
Next Earnings (Estimated): 2/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:NMRA
CUSIP: N/A
CIK: 1885522
Web: neumoratx.com
Phone: 857-760-0900
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.29
High Stock Price Target: $26.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +15.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.05
Quick Ratio: 18.05

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 152,700,000
Free Float: N/A
Market Cap: $2.81 billion
Optionable: Optionable
Beta: N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Paul L. Berns (Age 57)
Co-Founder & Executive Chairman
Comp: $879.58k
Mr. Joshua Pinto Ph.D. (Age 40)
CFO & Treasurer
Comp: $876.64k
Mr. Henry O. Gosebruch (Age 51)
President, CEO & Director
Ms. Carol Suh (Age 35)
Co-Founder & COO
Dr. Robert Michael Poole FACP (Age 67)
M.D., Co-Founder & Advisor
Dr. Rajesh Manchanda Ph.D. (Age 58)
Chief Technical Operations Officer
Mr. Nicholas Brandon Ph.D. (Age 50)
Chief Scientific Officer
Mr. Jason G. Duncan (Age 50)
Chief Legal Officer
Amy Sullivan
Senior Vice President of Human Resources
Dr. John V. W. Reynders Ph.D.
Chief Data Sciences Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NMRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Neumora Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neumora Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NMRA shares.
View NMRA analyst ratings or view top-rated stocks.
What is Neumora Therapeutics' stock price target for 2024?: 7 analysts have issued 12 month target prices for Neumora Therapeutics' shares. Their NMRA share price targets range from $13.00 to $26.00. On average, they anticipate the company's share price to reach $21.29 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for NMRA or view top-rated stocks among Wall Street analysts.
How have NMRA shares performed in 2024?: Neumora Therapeutics' stock was trading at $17.05 at the start of the year. Since then, NMRA stock has increased by 8.0% and is now trading at $18.42.
View the best growth stocks for 2024 here.
When is Neumora Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NMRA earnings forecast.
How were Neumora Therapeutics' earnings last quarter?: Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.79.

When did Neumora Therapeutics IPO?: (NMRA) raised $250 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.
When does Neumora Therapeutics' lock-up period expire?: Neumora Therapeutics' lock-up period expires on Wednesday, March 13th. Neumora Therapeutics had issued 14,710,000 shares in its IPO on September 15th. The total size of the offering was $250,070,000 based on an initial share price of $17.00. After the end of Neumora Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are Neumora Therapeutics' major shareholders?: Neumora Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (0.09%), Norges Bank (0.03%), New York State Common Retirement Fund (0.00%), SG Americas Securities LLC (0.00%), Strs Ohio (0.00%) and Amalgamated Bank (0.00%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Henry O Gosebruch and Kristina Burow.
View institutional ownership trends.
How do I buy shares of Neumora Therapeutics?: Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMRA) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Neumora Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

Short Interest

Short Interest

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Earnings and Valuation

Earnings Growth

About Neumora Therapeutics Stock (NASDAQ:NMRA)

NMRA Stock Price History

NMRA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NMRA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™